Pattern Bioscience Receives FDA Breakthrough Device Designation for Urine ID/AST Panel
Designation advances the company’s Urine (UTI) ID/AST Panel on Pattern’s single-cell microbiology platform. AUSTIN, Texas, September 21, 2026 — Pattern Bioscience, an innovator in rapid diagnostic technologies for bacterial infections, today announced that the U.S....Pattern Bioscience Appoints David Barreca as Vice President of Sales
Commercial leader in diagnostics joins Pattern to build US sales organization as the company nears FDA submission of its breakthrough single-cell microbiology platform and launch of the Pneumonia ID/AST Panel. AUSTIN, Texas, July 27, 2026 — Pattern Bioscience, an...
Pattern Bioscience Surpasses 1,000 Samples in Multi-Center Clinical Trial of Rapid Pneumonia Diagnostic
Milestone marks the half-way point of enrollment in pivotal U.S. study designed to support 510(k) submission for the first culture-free, rapid phenotypic ID/AST panel for critically ill pneumonia patients AUSTIN, Texas, March 19, 2026 — Pattern Bioscience, an...